Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson acquired 3,000 shares of Nymox Pharmaceutical Corporation stock in a transaction that occurred on Thursday, July 6th. The shares were bought at an average cost of $3.92 per share, with a total value of $11,760.00. Following the transaction, the director now owns 3,046,550 shares in the company, valued at $11,942,476. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

James George Robinson also recently made the following trade(s):

  • On Wednesday, July 5th, James George Robinson acquired 5,000 shares of Nymox Pharmaceutical Corporation stock. The shares were bought at an average cost of $3.97 per share, with a total value of $19,850.00.
  • On Friday, July 7th, James George Robinson bought 11,500 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $4.00 per share, with a total value of $46,000.00.
  • On Wednesday, June 28th, James George Robinson bought 8,500 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $4.09 per share, with a total value of $34,765.00.
  • On Monday, June 26th, James George Robinson bought 15,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $3.80 per share, with a total value of $57,000.00.
  • On Tuesday, June 20th, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $3.76 per share, with a total value of $18,800.00.
  • On Monday, June 19th, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $3.79 per share, with a total value of $18,950.00.
  • On Wednesday, June 21st, James George Robinson bought 15,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $3.77 per share, with a total value of $56,550.00.
  • On Tuesday, May 30th, James George Robinson bought 54,500 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $3.81 per share, with a total value of $207,645.00.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) remained flat at $4.13 during mid-day trading on Friday. The company’s stock had a trading volume of 106,422 shares. Nymox Pharmaceutical Corporation has a 12-month low of $1.62 and a 12-month high of $5.79. The firm’s market capitalization is $208.35 million. The firm’s 50-day moving average is $3.94 and its 200-day moving average is $3.61.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/07/07/insider-buying-nymox-pharmaceutical-corporation-nasdaqnymx-director-acquires-3000-shares-of-stock.html.

Separately, ValuEngine lowered Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, June 27th.

Nymox Pharmaceutical Corporation Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with MarketBeat.com's FREE daily email newsletter.